Work

Analysis of the Potential Effect of Ponatinib on the QTc Interval in Patients with Refractory Hematologic Malignancies

Year: 2011

Type: article

Source: Blood

DOI: 10.1182/blood.v118.21.4441.4441

Authors: Daryl Sonnichsen, David Dorer, Jorge E. Cortes, Moshe Talpaz, Michael W. Deininger, Neil Shah, Hagop M. Kantarjian, Dale Bixby, Michael J. Mauro, Ian W. Flinn, Jeffrey Litwin, Christopher D. Turner, Frank Haluska

Institutions: ARIAD Pharmaceuticals (United States), The University of Texas MD Anderson Cancer Center, University of Michigan, University of Utah, Huntsman Cancer Institute, University of California, San Francisco, Oregon Health & Science University, Sarah Cannon, Earth Resources Technology (United States)

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3025459697

FWCI:

Cites:

Cited by:

Related to: 10